You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

osimertinib resistance

Showing 1 - 25 of 8,125
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in

Not yet recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Cetuximab
  • +2 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 2, 2023

NSCLC Trial in Netherlands (Trastuzumab emtansine, Osimertinib)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Maastricht, Limburg, Netherlands
  • +4 more
Nov 7, 2022

Resistance to Tyrosine Kinase Inhibitor Osimertinib and

Recruiting
  • Lung Cancer
  • Blood Samples
  • Lorient, France
  • +3 more
Apr 26, 2022

Lung Cancer Trial in La Jolla (Abemaciclib, Osimertinib)

Recruiting
  • Lung Cancer
  • La Jolla, California
    UCSD Moores Cancer Center
Jan 20, 2021

Non-small-cell Lung Carcinoma Trial in Netherlands (biopsy, ctDAN analysis)

Recruiting
  • Non-small-cell Lung Carcinoma
  • biopsy
  • ctDAN analysis
  • Amsterdam, Noord-Holland, Netherlands
  • +5 more
Feb 2, 2021

Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19 Trial in France (Plasma ctDNA, FFPE blocks)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • Plasma ctDNA
  • FFPE blocks
  • Angers, France
  • +35 more
Sep 19, 2023

Lung Tumors, EGFR Gene Mutations Trial in Hwasun (Osimertinib)

Completed
  • Lung Neoplasms
  • EGFR Gene Mutations
  • Hwasun, Jeonnam, Korea, Republic of
    Chonnam National University Hwasun Hospital
Aug 1, 2021

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy Trial in Guangzhou (Toripalimab + Pemetrexed +

Unknown status
  • IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy
  • Toripalimab + Pemetrexed + Anlotinib
  • Guangzhou, Guangdong, China
    Zhou Chengzhi
Jul 22, 2020

Bronchial Tumors Trial in Germany, Spain (EGF816, Trametinib)

Recruiting
  • Bronchial Neoplasms
  • Cologne, Germany
  • +6 more
Nov 2, 2022

Combination of Osimertinib and Aspirin to Treat Osimertinib

Unknown status
  • Non-Small Cell Lung Cancer Stage IIIB
  • +2 more
  • (no location specified)
Jul 22, 2020

Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung

Active, not recruiting
  • Advanced Lung Non-Squamous Non-Small Cell Carcinoma
  • +5 more
  • Sacramento, California
  • +17 more
Aug 2, 2022

Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

Recruiting
  • Lung Neoplasm
  • +26 more
  • Boston, Massachusetts
  • +6 more
Jun 23, 2022

Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

Recruiting
  • Lung Neoplasms
  • +23 more
  • La Jolla, California
  • +35 more
Oct 6, 2022

Resistance to Oral Therapy in Lung Cancer

Completed
  • Non Small Cell Lung Cancer
  • Description of the molecular alterations detected in blood samples of patients treated by osimertinib
  • Montpellier, Hérault, France
    University Hospital
Dec 28, 2020

Double-dose Furmonertinib in Treatment of Slow

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • (no location specified)
Oct 31, 2023

Combination of Osimertinib and Aspirin to Treat 1st Generation

Unknown status
  • Non-Small Cell Lung Cancer Stage IIIB
  • +2 more
  • (no location specified)
Jul 22, 2020

NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)

Not yet recruiting
  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
  • (no location specified)
Aug 27, 2023

NSCLC Trial in Worldwide (Tepotinib, Osimertinib)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Yuma, Arizona
  • +178 more
Dec 19, 2022

Non Small Cell Lung Cancer Metastatic Trial in Worldwide (Osimertinib, Bevacizumab)

Active, not recruiting
  • Non Small Cell Lung Cancer Metastatic
  • Dublin, Ireland
  • +24 more
Aug 23, 2022

NSCLC Trial in Worldwide (Osimertinib + Savolitinib, Savolitinib + Placebo)

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • Osimertinib + Savolitinib
  • Savolitinib + Placebo
  • Duarte, California
  • +20 more
Dec 2, 2022

NSCLC Trial (Cobicistat)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
Feb 17, 2023

Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 Trial in United States

Recruiting
  • Lung Non-Small Cell Carcinoma
  • +5 more
  • San Francisco, California
  • +3 more
Aug 17, 2022

Osimertinib for NSCLC With Uncommon EGFR Mutations

Enrolling by invitation
  • Carcinoma, Non-Small-Cell Lung
  • Genes, erbB-1
  • Ramat Gan, Israel
    Sheba Medical Centre
Jun 14, 2022

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7

Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +3 more
  • New Haven, Connecticut
  • +4 more
Jan 27, 2023

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Duarte, California
  • +14 more
Jan 27, 2023